Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$PTCT Oppenheimer Provides Key Takeaways On PTC Therapeutics Following Data Presentation At WMS http://www.smarteranalyst.com/2014/10/14/oppenheimer-provides-key-takeaways-ptc-therapeutics-following-data-presentation-wms/
$AGEN Maxim Reiterates Buy On Agenus As Paradigm Shift Is Taking Hold In Immune-Based Therapeutics http://www.smarteranalyst.com/2014/10/14/maxim-reiterates-buy-agenus-paradigm-shift-taking-hold-immune-based-therapeutics/
$SRPT Oppenheimer Maintains Outperform On Sarepta As 3-Year Data Support Eteplirsen's Clinical Benefit http://www.smarteranalyst.com/2014/10/14/oppenheimer-maintains-outperform-sarepta-3-year-data-support-eteplirsens-clinical-benefit/
$SRPT Oppenheimer Maintains Outperform On Sarepta As 3-Year Data Support Eteplirsen's Clinical Benefit http://www.smarteranalyst.com/2014/10/14/oppenheimer-maintains-outperform-sarepta-3-year-data-support-eteplirsens-clinical-benefit/
Here's another one..
$OHRP Brean Capital Maintains Buy On OHR Pharmaceutical Following End Of Phase 2 Meeting With The FDA http://www.smarteranalyst.com/2014/10/14/brean-capital-maintains-buy-ohr-pharmaceutical-following-end-phase-2-meeting-fda/
$ATHN Oppenheimer Maintains Bearish View On Athenahealth Ahead Of 3Q14 Results http://www.smarteranalyst.com/2014/10/14/oppenheimer-maintains-bearish-view-athenahealth-ahead-3q14-results/
$PCYC Roth Capital Maintains Buy On Pharmacyclics Following Clinical Collaboration http://www.smarteranalyst.com/2014/10/14/roth-capital-maintains-buy-pharmacyclics-following-clinical-collaboration/
$INVN Roth Capital Reiterates Buy On InvenSense Ahead Of 2Q15 Earnings http://www.smarteranalyst.com/2014/10/13/roth-capital-reiterates-buy-invensense-ahead-2q15-earnings/
$RNA Roth Capital Reiterates Buy On Prosensa As It Begins NDA Submission For Drisapersen http://www.smarteranalyst.com/2014/10/13/roth-capital-reiterates-buy-prosensa-begins-nda-submission-drisapersen/
$KERX Keryx: Will NCE Matter? Roth Capital Doesn’t Think So; Reiterates Buy http://www.smarteranalyst.com/2014/10/13/keryx-will-nce-matter-roth-capital-doesnt-think-reiterates-buy/
$SRPT Sarepta Therapeutics: WMS Data Update Incrementally Positive, Says Roth Capital http://www.smarteranalyst.com/2014/10/13/sarepta-therapeutics-wms-data-update-incrementally-positive-says-roth-capital/
$SRPT Sarepta Therapeutics: WMS Data Update Incrementally Positive, Says Roth Capital http://www.smarteranalyst.com/2014/10/13/sarepta-therapeutics-wms-data-update-incrementally-positive-says-roth-capital/
$DSCI Derma Sciences: Valuation Is Unsustainably Low, Says Roth Capital; Reiterates Buy http://www.smarteranalyst.com/2014/10/13/derma-sciences-valuation-unsustainably-low-says-roth-capital-reiterates-buy/
$CAPR H.C. Wainwright Reiterates Buy On Capricor As It Plans To Pursue A Cenderitide Clinical Program http://www.smarteranalyst.com/2014/10/13/h-c-wainwright-reiterates-buy-capricor-plans-pursue-cenderitide-clinical-program/
$CUR Neuralstem Shares Are Currently Fairly Valued, Says H.C. Wainwright http://www.smarteranalyst.com/2014/10/13/neuralstem-shares-currently-fairly-valued-says-h-c-wainwright/
$CUR Neuralstem Shares Are Currently Fairly Valued, Says H.C. Wainwright http://www.smarteranalyst.com/2014/10/13/neuralstem-shares-currently-fairly-valued-says-h-c-wainwright/
$ENDP Endo: The Worst Is Over And There Is More Visibility Into Longer-Term Growth, Says Cantor http://www.smarteranalyst.com/2014/10/13/endo-worst-visibility-longer-term-growth-says-cantor/
$MNTA Maxim Group Reiterates Buy On Momenta Pharmaceuticals Following R&D Day http://www.smarteranalyst.com/2014/10/13/maxim-group-reiterates-buy-momenta-pharmaceuticals-following-rd-day/
$MNTA Maxim Group Reiterates Buy On Momenta Pharmaceuticals Following R&D Day http://www.smarteranalyst.com/2014/10/13/maxim-group-reiterates-buy-momenta-pharmaceuticals-following-rd-day/
$CMRX Brean Capital Maintains Buy On Chimerix Following Preliminary Data Release At IDWeek 2014 Meeting http://www.smarteranalyst.com/2014/10/13/brean-capital-maintains-buy-chimerix-following-preliminary-data-release-idweek-2014-meeting/
$RPRX Repros Therapeutics: PRAC Conclusion On TRT Helps Case For Androxal, Says Brean Capital http://www.smarteranalyst.com/2014/10/13/repros-therapeutics-prac-conclusion-trt-helps-case-androxal-says-brean-capital/
$INFY Oppenheimer Maintains Perform On Infosys As Shares Appear Reasonably Valued http://www.smarteranalyst.com/2014/10/13/oppenheimer-maintains-perform-infosys-shares-appear-reasonably-valued/
$BDSI Roth Capital Downgrades BioDelivery To Neutral As Upside Seems Limited At Current Levels http://www.smarteranalyst.com/2014/10/10/roth-capital-downgrades-biodelivery-to-neutral-as-upside-seems-limited-at-current-levels/
$BDSI Roth Capital Downgrades BioDelivery To Neutral As Upside Seems Limited At Current Levels http://www.smarteranalyst.com/2014/10/10/roth-capital-downgrades-biodelivery-to-neutral-as-upside-seems-limited-at-current-levels/
$EBAY Cantor Fitzgerald Reaffirms Buy On Ebay Ahead Of Release Of 3Q14 Results http://www.smarteranalyst.com/2014/10/10/cantor-fitzgerald-reaffirms-buy-ebay-ahead-release-3q14-results/
$EBAY Cantor Fitzgerald Reaffirms Buy On Ebay Ahead Of Release Of 3Q14 Results http://www.smarteranalyst.com/2014/10/10/cantor-fitzgerald-reaffirms-buy-ebay-ahead-release-3q14-results/
$GOOG Cantor Fitzgerald Maintains Buy On Google Ahead Of 3Q14 Results http://www.smarteranalyst.com/2014/10/10/cantor-fitzgerald-maintains-buy-google-ahead-3q14-results/
$GOOG Cantor Fitzgerald Maintains Buy On Google Ahead Of 3Q14 Results http://www.smarteranalyst.com/2014/10/10/cantor-fitzgerald-maintains-buy-google-ahead-3q14-results/
$NFLX Cantor Fitzgerald Maintains Buy On Netflix Ahead Of 3Q14 Results http://www.smarteranalyst.com/2014/10/10/cantor-fitzgerald-maintains-buy-netflix-ahead-3q14-results/
$NFLX Cantor Fitzgerald Maintains Buy On Netflix Ahead Of 3Q14 Results http://www.smarteranalyst.com/2014/10/10/cantor-fitzgerald-maintains-buy-netflix-ahead-3q14-results/
$EXAS William Blair Maintains Outperform On Exact Sciences As It Received $502 Reimbursement For Cologuard http://www.smarteranalyst.com/2014/10/10/william-blair-assigns-outperform-exact-sciences-corp-shares/
$EXAS William Blair Maintains Outperform On Exact Sciences As It Received $502 Reimbursement For Cologuard http://www.smarteranalyst.com/2014/10/10/william-blair-assigns-outperform-exact-sciences-corp-shares/
$ARIA William Blair Remains Positive On Ariad On The Heels Of Favorable PRAC Review for Iclusig http://www.smarteranalyst.com/2014/10/10/william-blair-remains-positive-ariad-heels-favorable-prac-review-iclusig/
$ARIA William Blair Remains Positive On Ariad On The Heels Of Favorable PRAC Review for Iclusig http://www.smarteranalyst.com/2014/10/10/william-blair-remains-positive-ariad-heels-favorable-prac-review-iclusig/
$GILD UPDATE: Cowen Maintains Bullish Stance On Gilead Sciences Following Harvoni FDA Approval http://www.smarteranalyst.com/2014/10/10/update-cowen-maintains-bullish-stance-gilead-sciences-following-harvoni-fda-approval/
$GILD UPDATE: Cowen Maintains Bullish Stance On Gilead Sciences Following Harvoni FDA Approval http://www.smarteranalyst.com/2014/10/10/update-cowen-maintains-bullish-stance-gilead-sciences-following-harvoni-fda-approval/
$JNPR Juniper Networks: 4Q14/1Q15 Outlook is Unclear, Says UBS Analyst http://www.smarteranalyst.com/2014/10/10/juniper-networks-4q141q15-outlook-is-unclear-says-ubs-analyst/
$PEP UBS Maintains Buy On PepsiCo Following 3Q14 Results; Slightly Raises Price Target http://www.smarteranalyst.com/2014/10/10/ubs-maintains-buy-pepsico-following-3q14-results-slightly-raises-price-target/
$PEP UBS Maintains Buy On PepsiCo Following 3Q14 Results; Slightly Raises Price Target http://www.smarteranalyst.com/2014/10/10/ubs-maintains-buy-pepsico-following-3q14-results-slightly-raises-price-target/
$MNTA Maxim Group Maintains Buy On Momenta Following Phase 1/2 Trial Results Of Necuparanib http://www.smarteranalyst.com/2014/10/10/maxim-group-maintains-buy-momenta-following-phase-12-trial-results-necuparanib/